PURPOSE: To report the effect of anti-vascular endothelial growth factor (VEGF) therapy for choroidal neovascularization overlying choroidal osteoma. METHOD: In an interventional case report, intravitreal anti-VEGF therapy was used for tumor-related choroidal neovascularization. RESULTS: A 34-year-old woman with bilateral choroidal osteoma had a decrease in visual acuity in the right eye from 20/30 to 20/100. Ophthalmoscopy revealed partially decalcified circumpapillary, macular choroidal osteoma with overlying subretinal hemorrhage and choroidal neovascular membrane. Intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) resulted in membrane regression and visual acuity improvement to 20/50 at 6 weeks. Further therapy with intravitreal ranibizumab (Lucentis; Genentech, Inc.) resolved persistent subretinal fluid, and visual acuity improved to 20/30 at the 6-month follow-up. CONCLUSIONS: Therapy with intravitreal anti-VEGF medications might be an alternative for patients with choroidal neovascularization overlying choroidal osteoma.
PURPOSE: To report the effect of anti-vascular endothelial growth factor (VEGF) therapy for choroidal neovascularization overlying choroidal osteoma. METHOD: In an interventional case report, intravitreal anti-VEGF therapy was used for tumor-related choroidal neovascularization. RESULTS: A 34-year-old woman with bilateral choroidal osteoma had a decrease in visual acuity in the right eye from 20/30 to 20/100. Ophthalmoscopy revealed partially decalcified circumpapillary, macular choroidal osteoma with overlying subretinal hemorrhage and choroidal neovascular membrane. Intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) resulted in membrane regression and visual acuity improvement to 20/50 at 6 weeks. Further therapy with intravitreal ranibizumab (Lucentis; Genentech, Inc.) resolved persistent subretinal fluid, and visual acuity improved to 20/30 at the 6-month follow-up. CONCLUSIONS: Therapy with intravitreal anti-VEGF medications might be an alternative for patients with choroidal neovascularization overlying choroidal osteoma.
Authors: V P Papastefanou; M Pefkianaki; L Al Harby; A K Arora; V M L Cohen; R M Andrews; M S Sagoo Journal: Eye (Lond) Date: 2016-04-01 Impact factor: 3.775
Authors: Ahmad M Mansour; J Fernando Arevalo; Eman Al Kahtani; Hernando Zegarra; Emad Abboud; Rajiv Anand; Hamid Ahmadieh; Robert A Sisk; Salman Mirza; Samuray Tuncer; Amparo Navea Tejerina; Jorge Mataix; Francisco J Ascaso; Jose S Pulido; Rainer Guthoff; Winfried Goebel; Young Jung Roh; Alay S Banker; Ronald C Gentile; Isabel Alonso Martinez; Rodney Morris; Neeraj Panday; Park Jung Min; Emilie Mercé; Timothy Y Y Lai; Vicky Massoud; Nicola G Ghazi Journal: J Ophthalmol Date: 2014-07-23 Impact factor: 1.909